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ABSTRACT
Objectives: Applications to run clinical trials in
Europe fell 25% between 2007 and 2011. Costs, speed
of approvals and shortcomings of European Clinical
Trial Directive are commonly invoked to explain this
unsatisfactory performance. However, no hard evidence
is available on the actual weight of these factors or has
it been previously investigated whether other criteria
may also impact clinical trial site selection.
Design: The Survey of Attitudes towards Trial sites in
Europe (SAT-EU Study) was an anonymous, cross-
sectional web-based survey that systematically
assessed factors impacting European clinical trial site
selection. It explored 19 factors across investigator-
driven, hospital-driven and environment-driven criteria,
and costs. It also surveyed perceptions of the
European trial environment.
Setting and participants: Clinical research
organisations (CROs), academic clinical trial units
(CTUs) and industry invited to respond.
Outcome measures: Primary outcome: weight
assigned to each factor hypothesised to impact trial
site selection and trial incidence. Secondary outcome:
desirability of European countries to run clinical trials.
Results: Responses were obtained from 485
professionals in 34 countries: 49% from BioPharma,
40% from CTUs or CROs. Investigator-dependent,
environment-dependent and hospital-dependent factors
were rated highly important, costs being less important
(p<0.0001). Within environment-driven criteria, pool of
eligible patients, speed of approvals and presence of
disease-management networks were significantly more
important than costs or government financial
incentives (p<0.0001). The pattern of response was
consistent across respondent groupings (CTU vs CRO
vs industry). Considerable variability was demonstrated
in the perceived receptivity of countries to undertake
clinical trials, with Germany, the UK and the
Netherlands rated the best trial markets (p<0.0001).
Conclusions: Investigator-dependent factors and ease
of approval dominate trial site selection, while costs
appear less important. Fostering competitiveness of
European clinical research may not require additional
government spending/incentives. Rather,
harmonisation of approval processes, greater visibility
of centres of excellence and reduction of ‘hidden’
indirect costs, may bring significantly more clinical
trials to Europe.
INTRODUCTION
Europe has consistently expressed a desire to
maintain and improve clinical trial competi-
tiveness,1–3 most recently by advocating a
‘European Research Area’ in which
‘researchers, scientiﬁc knowledge and tech-
nology circulate freely’.4 A major component
of the European governance for clinical
research, European Clinical Trial Directive
2001/20/EC (CTD) was intended to support
this goal, focusing on the harmonisation of
Strengths and limitations of this study
▪ We provide systematic evidence across a large
sample of expert professionals indicating that
fostering competitiveness of European clinical
research may not require additional government
spending/incentives. Carefully crafted harmonisa-
tion of approvals, greater visibility of centres of
excellence via disease networks/the web, and
reduction of ‘hidden’ costs are more likely to
boost competitiveness of European clinical
research.
▪ Consistent with voluntary surveys, we could only
analyse responses provided by those interested
in replying, and therefore cannot exclude that
other points of view may have emerged from
those who did not participate; our questionnaire
may also have missed potentially important
factors.
▪ Carefully crafted harmonisation of approvals,
greater visibility of centres of excellence via
disease networks/the web, and reduction in
‘hidden’ costs are more likely to boost the com-
petitiveness of European clinical research.
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research processes across EU member states.5–9 However,
the CTD failed to achieve its intended impact on the
simpliﬁcation and harmonisation of administrative provi-
sions governing clinical trials,9 and thus on the level of
European clinical research activity.2 10 11 In fact, from
2007 to 2011, the number of clinical trial applications in
Europe fell 25%.12 Accordingly, although concerted
calls for further CTD revisions continue13 14 and recom-
mendations awaiting member state review have been
made by the European Commission6 and endorsed by
scientiﬁc societies,15 it is not clear which speciﬁc recom-
mendations should be implemented or prioritised at
either national or pan-European level.
Much of this uncertainty stems from an insufﬁcient
understanding of the key drivers determining decision
made by the healthcare industry, academic clinical trial
units (CTUs) and clinical research organisations
(CROs) in selecting European trial sites. Furthermore,
although it is widely believed that costs and speed of
approval are key factors inﬂuencing clinical trial inci-
dence in Europe,6 16 the relative weight of these and
other important criteria is poorly understood. To our
knowledge, no published studies have examined country
and site selection criteria for trials conducted in Europe.
Evidence is therefore needed to improve our under-
standing of stakeholders’ decision-making process.
The Survey of Attitudes towards Trial sites in Europe
(the SAT-EU Study) was established as a non-proﬁt col-
laborative effort to systematically assess factors impacting
clinical trial site selection in Europe. We also investi-
gated whether trial selection needs differ between
academic and commercial sponsors. Finally, the survey
sought to explore perceptions of the current European
trial environment, and to identify areas for future
improvement.
METHODS
Survey design
The SAT-EU Study was an anonymous web-based cross-
sectional survey undertaken between 26 September 2011
and 21 January 2012. It included all stakeholder groups
involved in clinical trial site selection, that is, BioPharma
companies, medical device manufacturers, CROs and
CTUs. The survey sought to capture information on
early-phase and late-phase studies. Late-phase studies
were deﬁned as phase III for CTUs, BioPharma and
their subcontractors (ie, CROs) and phase IV for other
participants (eg, medical device companies).
A multistage approach was used to develop the survey.
First, we identiﬁed the main criteria expected to impact
site selection. Second, we organised these into four
broad categories: (1) investigator related, (2) hospital/
institution related, (3) country/environment related and
(4) costs (evaluated separately and within the environ-
ment category). Third, the deﬁned criteria underwent
review and discussion with a small number of knowl-
edgeable professionals to ensure that potentially relevant
criteria had not been missed (ﬁgure 1).
The study group then built an internet-based survey
hosted on a freely accessible online questionnaire soft-
ware (Survey Monkey, Palo Alto, California, USA).
Figure 1 Hypothesis about trial site selection criteria. Four categories of levers potentially impacting trial site selection were
identified. Survey-weighed relevance across these four levers, then drilled down for weight within each subcategory.
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Before launching the survey, healthcare market research
experts (The Planning Shop International, London,
UK) reviewed the survey design to optimise content and
minimise bias. Additionally, a pilot survey undertaken by
15 respondents in June 2011 was used to validate and
reﬁne question content and organisation.
Survey procedure
The survey consisted of 23 questions, which took some
20 min to complete. In sequence, questions asked parti-
cipants to (1) provide demographic information
anonymously (2) rate the importance of each of the
hypothesised trial site selection criteria for Europe as a
whole, (3) provide perception of the trial environment
in 12 European countries and (4) rank areas of poten-
tial improvement. Participants’ feedback was assessed
using a multiple-choice format, requiring respondents to
provide a single response of rank. The full set of ques-
tions is accessible at http://www.sbg-marcom.ch/sat-eu/
Study_plan.html. The order of presentation of individual
responses to each question was scrambled across respon-
dents to minimise response bias. At the end of each
section, a response box allowed participants to provide
open text comments, available as an ‘online supple-
ment’. Results of the survey were thoroughly reviewed
among the study group, and subsequently discussed with
a 25-member expert panel in Brussels on November
2012.
The survey was advertised through industry and clin-
ical trial associations, online communities, social net-
works and personal contacts of the SAT-EU Study
group,17 so that the precise number of people invited to
participate is not known. No remuneration was provided
to participants, but respondents were offered a summary
of survey results once available.
Statistical analysis
Given the descriptive nature of the SAT-EU Study
design, we did not formally estimate a required sample
size. Instead, we sought to obtain at least 150 completed
questionnaires from across the four stakeholder groups.
Results are primarily presented descriptively as means
(and 95% CI), or medians (and upper and lower quar-
tiles), as appropriate to show results by group or
country. Where data were available, responses were com-
pared across three survey respondent groupings (ie,
CTU vs CRO vs industry), and across responses within
each survey question, using one-way analysis of variance.
RESULTS
A total of 485 individual responses were obtained, with
participants providing responses to 72% of questions on
average. Responders represented over 100 different insti-
tutions, including over 50 pharmaceutical, biotechnol-
ogy or medical device ﬁrms and over 20 CROs and
CTUs.
Respondent demographics
Respondents represented over 37 countries, the top ﬁve
contributors being Italy, USA, the UK, Germany and
Spain (table 1). Participants were almost evenly split
between BioPharma (49%) and CROs/CTUs (40%;
ﬁgure 2). In terms of hierarchy/job description, 43%
were vice president, director or manager in a research
or marketing position, and an additional 20% were head
of a CTU (ﬁgure 3, left panel). The majority of respon-
dents described themselves as being directly involved in
trial site selection decisions; almost two-thirds either per-
sonally headed, or sat on the trial site selection commit-
tee of their organisation (ﬁgure 3, right panel).
Importantly, most respondents were the ﬁnal decision-
makers, stating that they were either the ‘overall ﬁnal
decision maker’, or that trial site selection decisions
were ‘entirely at (their) discretion’.
Table 1 Respondent work location (N=485)
Country Respondents
Australia 1
Austria 4
Belgium 21
Brazil 1
Bulgaria 3
Canada 6
China 1
Croatia 1
Czech Republic 1
Denmark 21
Egypt 1
Estonia 1
Finland 11
France 21
Germany 46
Greece 4
Hungary 4
India 13
Ireland 8
Israel 5
Italy 75
The Netherlands 16
Nigeria 1
Norway 1
Poland 7
Portugal 9
Romania 7
Russia 1
Serbia 1
Slovakia 1
Slovenia 2
Spain 44
Sweden 13
Switzerland 20
Ukraine 1
The UK 48
USA 58
Not available 6
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Relevance of investigator, environment, hospital
and costs criteria
Respondents were asked to divide 100 points (reﬂecting
their perceived level of importance) across four
categories of factors impacting trial site selection. For
early-phase and late-phase trials (as deﬁned in the
Methods section), factors pertaining to the investigator,
the hospital/unit and the environment, were rated at a
Figure 2 Respondent’s organisation. Respondents were asked to answer the question: “Please indicate which organisation
most closely resembles yours.” Bars show percentage distribution of 485 individual responses. Biotech, biotechnology
companies; CRO, clinical research organisation; CTU, clinical trial unit; medical devices, radiological, electromedical or
healthcare information technology; pharma, pharmaceutical companies; other included following self-reported categories:
respondent working for a mixed portfolio industry with either pharma/biotech portfolio or pharma/medical device portfolio (self
reported); regulatory/clinical consultant, hospital or private clinic.
Figure 3 Left panel: respondent hierarchy. Respondents were asked to answer the question: “Please indicate the position
which most closely resembles yours.” Chart shows percentage distribution of 485 individual responses. VP, Vice President.
‘Other’ were respondents who wanted to be more specific in their titles: global study manager/clinical research associate (CRA);
regulatory affairs/regulatory in a clinical department/good clinical practice quality assurance manager or director/safety
pharmacovigilance officer; medical affairs/medical director/clinical director/global scientific affairs; and general manager. Right
panel: respondent organisation’s decision-making process. Respondents were asked to answer the question: “Please indicate
which most closely resembles how trial site selection decisions are made at your institution.” Chart shows percentage distribution
of 485 individual responses. Other (11.8%) included: my staff decides; decision outsourced to CRO; clinical research associate
decides; decisions according to standard operating procedures; many people involved in decision; study team decides; our
affiliates decide.
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high level of importance (25 or above; table 2). When
combined, investigator-dependent and hospital-
dependent levers were reported to be instrumental in
trial site choice for early-phase and late-phase studies
(average weight 60/100 and 57/100, respectively). In
contrast, cost factors were considered to be less import-
ant for early-phase and late-trials (p<0.0001; table 2).
This pattern of response was consistent across survey
respondent groupings (ie, CTU vs CRO vs industry; not
shown).
Investigator-driven criteria
Respondents were asked to assign 100 points across ﬁve
investigator-related criteria. There was a statistically sig-
niﬁcant difference in the level of importance of the
factors tested, with investigator track record in previous
trials, experience in similar studies and interest in study
scoring a level of importance of 20 or above, while con-
current trial workload, and publication track record
were signiﬁcantly less important (p<0.0001; table 3).
The pattern of response was again consistent across
survey respondent groupings (not shown).
Environment-driven criteria
To explore environmental dynamics, respondents were
asked to assign 100 points across six environment-related
criteria. Market size/pool of eligible patients in the
region, speed of approvals and presence of disease man-
agement networks, were assigned a greater level of
importance. In contrast, costs of running trials, and par-
ticularly government ﬁnancial/tax incentives were con-
sidered to be of signiﬁcantly lower importance
(p<0.0001; table 4). Also in this case, the pattern of
response was consistent across survey respondent group-
ings (not shown).
Hospital-driven criteria
In this domain, 100 points had to be assigned across six
criteria that explored characteristics of the speciﬁc hos-
pital/unit where a clinical trial may potentially be run.
There was a statistically signiﬁcant difference in the level
of importance of hospital-driven criteria, whereby site
personnel experience and training, respondent’s previ-
ous experience with site, and availability of facilities and
equipment required by trial scored above 20
(p<0.0001). In contrast, site personnel language capabil-
ities and hospital quality assurance processes were sig-
niﬁcantly less important (table 5).
Perception of European trial environment
Our survey showed a statistically signiﬁcant difference
in respondents’ perceived desirability of running clin-
ical trials across the 12 European countries tested, that
is, Europe’s top ﬁve healthcare markets (Germany,
France, Italy, the UK and Spain), large east European
markets (Poland, Hungary and Czech Republic), plus
the Netherlands, Belgium, Switzerland and Austria. For
accessibility and transparency of all information
required to run clinical trials (ﬁgure 4, upper panel),
and availability of equipment (not shown), Germany,
the UK and the Netherlands were the top three
scorers. With regard to predictability and speed of
ethics committees, Belgium was the top scorer, followed
by Germany and the Netherlands (ﬁgure 4, lower
panel). In terms of overall trial site ‘desirability’,
respondents scored Germany as the most desirable trial
location, followed by the Netherlands and the UK
(p=0.0001; ﬁgure 5).
Possible improvements
Two questions tested the hypothesis that making a site
more visible would be desirable from the decision-
makers’ perspective. We found that 83% of respondents
would have been ‘much more likely’ to include a site if
all relevant investigator-related and hospital-related
information were readily available (ﬁgure 6, left panel).
Furthermore, 75% believed that web-site information
would be either ‘deﬁnitely welcome’, or ‘useful most of
the time’ (ﬁgure 6, right panel).
DISCUSSION
The SAT-EU Study was a web-based survey designed to
identify perceived drivers and hurdles associated with
conducting clinical trials in Europe. We obtained
Table 2 Levers impacting trial site selection for early and late trials
Lever
Response mean Upper 95% CL Lower 95% CL
Early phase Late phase Early phase Late phase Early phase Late phase
Investigator factors 30.2 29.1 31.5 30.4 28.9 27.8
Hospital/unit factors 28.4 28.3 29.7 29.7 27.0 26.9
Environmental factors 25.5 23.5 26.6 24.7 24.3 22.4
Cost factors 16.0 19.0 17.2 20.4 14.7 17.7
Respondents (N=341) were asked to divide 100 points across the above four levers impacting their trial site selection for early phase studies:
Pharma, Biotech, CROs and CTUs answered for phase II (2) studies. Medical device and all others answered for phase III (3) studies. Then
respondents were asked to do the same as above for later phase studies: Pharma, Biotech, CROs and CTUs answered for phase III (3)
studies. Medical device and all others answered for phase IV (4) studies. There was evidence of a statistically significant difference in the
level of importance of the four factors (p<0.0001). The pattern of response (not shown here) appeared to be consistent across survey
respondent groupings (ie, CTU vs CRO vs industry).
CL, confidence limit; CROs, clinical research organisations; CTUs, clinical trial units.
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responses from over 400 participants in key stakeholder
groups, that is, BioPharma industry, medical device man-
ufacturers, CROs and CTUs. The vast majority of coun-
tries actively involved in clinical trials were represented,
while most respondents were key decision-makers in
their organisations. These features allowed us to get
direct and potentially relevant insights into the reason-
ing behind site selection for clinical trials.
Recent years have seen much public policy discussion
on the need to foster Europe’s role in medical research,
and to rekindle its dwindling attractiveness for invest-
ment in clinical trials.18–20 Various strategies have been
proposed based on a ‘common sense’ approach. While
possibly sound, policy recommendations were typically
not founded on a systematic understanding of factors
impacting clinical trial site selection. Indeed, one could
argue that, borrowing from the rigour of its own discip-
line, medical policy decisions at all levels ought to be
‘evidence based’. Regretfully however, this approach
seems to be largely absent. To our knowledge, the
SAT-EU Study is the ﬁrst effort aimed at systematically
investigating factors impacting trial site attractiveness
across Europe. Given the survey’s size, the variety of
domains explored, the number of countries and organi-
sations involved, and the prevalence of senior decision-
makers, our results may provide insight into ‘real world’
trial site decisions.
Our study has several key ﬁndings. First, there was evi-
dence of considerable variability in the perceived recep-
tivity of European countries to undertake clinical trials,
Germany, the UK and the Netherlands being rated the
best markets. Reasons for greater appeal of certain coun-
tries are multiple. Larger countries could be more
attractive because of greater patient recruitment poten-
tial, and in prospect, because of the size of their
markets. However, country size does not entirely explain
the phenomenon, given the excellent results of small
countries such as the Netherlands, and the low score of
large countries such as Italy or Spain. Our survey sheds
some light on this by pointing to the negative impact of
administrative burden on clinical trial competitiveness.
This is not only a concern at country level. Central to
this discussion is the notion that the time required to
collect information to determine a site’s feasibility for
inclusion in a trial, and to get it started, is also critical.
Hence, the high weight placed on a site’s proven track
record in efﬁciently delivering results, which bears a
relationship to specialised clinical research centres, and
equally important, to the ability of clinical trial sponsors
and organisers to access all of the required information
quickly and effectively. Accordingly, the downsides of
operating within a suboptimal regulatory environment
may not prejudice selection of an otherwise visible and
competent investigator, whose trial site information is
readily available and who is able to recruit the required
patients. A third important ﬁnding of our survey is that
contrary to a widely held tenet, costs of running trials—
often invoked to explain why industry is going outside
Europe6 16—as well as government incentives/tax
breaks, are not the main considerations when selecting
European sites. In other words, it would seem from sta-
keholders’ feedback and follow-up discussions that to
Table 3 Investigator-driven criteria in the selection of phase II–III trial sites (phase III–IV for medical device)
Criteria Mean Upper 95% CL Lower 95% CL SD
Investigator recruitment/retention track record 27.3 28.5 22.4 13.3
Investigator experience in previous trials 22.7 23.8 21.6 12.0
Investigator interest 22.42 23.6 21.3 13.4
Investigator concurrent workload 17.2 18.2 16.2 9.8
Investigator publication track record 10.4 11.3 9.6 10.9
Respondents (N=341) were asked to divide 100 points across the above five criteria when selecting trial sites for phase III/IV (3/4) studies:
Pharma, Biotech, CROs and CTUs answered for phase III (3) studies. Medical device and all others answered for phase IV (4) studies. There
was evidence of a statistically significant difference in the level of importance of the five criteria (p<0.0001). The pattern of response (not
shown here) appeared to be consistent across survey respondent groupings (ie, CTU vs CRO vs industry).
CL, confidence limit; CROs, clinical research organisations; CTUs, clinical trial units.
Table 4 Environment-driven criteria in the selection of phase II–III trial sites (phase III–IV for medical devices)
Criteria Mean Upper 95% CL Lower 95% CL SD
Size of market/eligible patients in a region 23.8 25.2 22.4 13.3
Speed of MoH/ethics committees approval 23.4 24.6 22.1 12.0
Disease management system/networks 18.9 20.4 17.5 13.4
Cost of running trial 15.2 16.3 14.2 9.8
Presence of country on ‘core country list’ 11.8 13.0 10.7 10.9
Government financial/tax incentives 6.9 7.6 6.2 6.6
Respondents (N=341) were asked to divide 100 points across the above six criteria when selecting trial sites for phase III/IV (3/4) studies:
Pharma, Biotech, CROs and CTUs answered for phase III (3) studies. Medical device and all others answered for phase IV (4) studies. There
was evidence of a statistically significant difference in the level of importance of the six criteria (p<0.0001).
CL, confidence limit; CROs, clinical research organisations; CTUs, clinical trial units; MoH, Ministry of Health.
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the extent that European centres may be excluded from
a trial, the likely culprit is the hidden costs associated
with excessive administrative time required to get a trial
site up and running, not the high fees per enrolled
patient. Although apparently surprising, the limited
impact of costs needs to be considered against the back-
drop of the various issues to which our survey tried to
provide a response. Indeed, in addition to ‘direct’ costs,
a major negative factor is represented by indirect, or
‘hidden’ costs, such as those characterised by time lost
through layers of bureaucracy, slow recruitment by sites
or poor overall site performance. Hence, the import-
ance of not only bureaucracy, but also of the level of
training and trial expertise at sites. Additionally, the
notion that investments in clinical trials in Europe
cannot be easily improved through government
Table 5 Hospital-driven criteria in the selection of phase II–III trial sites (phase III–IV for medical devices)
Mean Upper 95% CL Lower 95% CL
Site personnel experience and training 22.0 23.1 20.84
Previous experience with site 20.0 21.2 18.7
Facilities/equipment required by trial 19.7 20.7 18.7
Hospital approval/contracting system 17.4 18.5 16.4
Site personnel language proficiency 10.8 11.7 10.0
Hospital quality assurance process 10.1 10.9 9.2
Respondents (N=341) were asked to rate hospital-driven criteria by dividing 100 points across six criteria potentially used when selecting trial
sites for phase III studies: Pharma, Biotech, CROs and CTUs answered for phase III studies. Medical device and all others answered for
phase IV studies. There was evidence of a statistically significant difference in the level of importance of the six criteria (p<0.0001).
CL, confidence limit; CROs, clinical research organisations; CTUs, clinical trial units.
Figure 4 Upper panel: accessibility and transparency of all types of information required to make trial site selection decisions—
12 country rank (N=296). Respondents were asked to rate 12 countries for the accessibility and transparency of information (of
all types) required to make trial site selection. Bars represent mean and 95% CI. Statistically significant difference in satisfaction
across European Union (EU) countries (p=0.0001). Lower panel: predictability and speed of ethics committees and institutional
review boards (IRBs) for phase II–III multicentre randomised controlled trials (RCTs)—12 country rank (N=296). Respondents
were asked to rate 12 countries for the speed of their ethics committees and Institutional Review Boards for phase III (3)
multicentric RCTs. Bars represent mean and 95% CI (number of respondents in parentheses). Statistically significant difference
in satisfaction across EU countries (p=0.0001).
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incentives or tax breaks may have important implications
in terms of public policy. Comments obtained through
our survey seem to indicate that stakeholders would like
a single European ‘trial market’ allowing them to gear
trial site selection to expert investigators and to optimal
patient recruitment, unobstructed by heterogeneous reg-
ulations or hurdles in obtaining crucial information.
Participants expressed this need in two main ways. First,
from a regulatory or ‘macro’ perspective, they expressed
desire for easier approval processes with less national
variability and stronger pan-European element. This
may indicate ethical committee approval timeframes, as
well as institutional approvals at site level. Second, from
a clinical research or ‘micro’ perspective, respondents
Figure 5 Trial site desirability by country. Trial site desirability ‘index’—nine country rank (N=296; ordered by median).
Respondents were asked to provide their ‘personal perception’ ranking of the desirability of running trials in nine countries,
ranking them from ‘1’ ‘most desirable’ country to ‘9’ ‘least desirable’ country (if needed, they could click ‘no opinion’ in up to three
countries they know the least). Data are presented as whisker-box plot of median and lower and upper quartile. There was
evidence of a statistically significant difference in the perceived desirability of running trials across European Union countries
(p=0.0001).
Figure 6 Left panel: likelihood of selecting trial site given relevant information. Respondents were asked to rate their level of
agreement with the statement: “I am much more likely to select a trial site if I have all of the relevant Investigator and Site specific
information easily available to me.” Chart represents percentage response (N=253). Right panel: usefulness of trial site website
information. Respondents were asked to pick the statement that they felt closest to with reference to the assertion that “it would
be useful to have relevant trial information readily visible in a dedicated public section the Hospital’s website (facilities,
equipment, personnel qualification, Ethics Committee and Institutional Review Board timings, contact people for trials, etc).”
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want access to transnational networks of disease-area
experts, through visibility of experienced trial units via
the internet and/or via participation in disease
networks.
More than 50 years ago, the founders of the EU envi-
sioned a single market at the core of the European
project. Despite this, a ‘single market’ vision for clinical
research did not develop as envisaged. This is damaging
to an industry in which much of the investment in clinical
trials is by necessity multinationals. Indeed, Europe’s
2020 growth strategy calls for 3% of its Gross National
Product to be invested in research and development
(R&D) by 2020.21 If this goal is to be achieved,
BioPharma—the European sector with the highest R&D/
sales ratio22—should be allowed to invest in Europe
without facing unnecessary roadblocks. Given the size of
its healthcare market, its ageing population, its well-
established pharmaceutical industry and the quality of its
research centres and investigators, Europe has a formid-
able comparative advantage in clinical research.
Individual European member states are well poised to
take advantage of this by making the EU more competi-
tive in clinical research. They should be encouraged to
do so, not simply by investing in incentives or tax breaks,
but by implementing revisions to the CTD that are under
consideration by member states, and by legislating
removal of unhelpful bureaucratic barriers at national
level. Improving hospital contracting, such as via national
or even pan-European contract templates, would also sig-
niﬁcantly reduce administrative burden, speed up trial
start and make the European landscape signiﬁcantly
more competitive. On their part, the research community
and relevant national bodies have a parallel imperative to
ensure that hospitals and institutions are organised and
networked more effectively, and that there is adequate
training of trial staff. They need to ensure that clinical
centres wishing to undertake more research are made
more visible to industry and to international research
communities, through dedicated research portals on
their websites, or by creating and/or joining disease net-
works. Finally, given that selected countries are consist-
ently scored above others, a best practice audit of
administrative provisions governing and supporting clin-
ical trials in countries such as Germany, the UK and the
Netherlands14 would be helpful for drawing policy impli-
cations for other countries. The case for action rests on
the realisation that evidence-based policy is indeed pos-
sible in this arena. Learning from what is working success-
fully will facilitate the road to creating a more welcoming
environment for clinical research in Europe.
LIMITATIONS
Consistent with voluntary surveys, we could only analyse
responses provided by those who were interested in
replying, and therefore we cannot exclude that other
points of view may have emerged from those who did
not participate. Nonetheless, it is rather reassuring that
the responses were gathered through a fairly large
number of professionals who belonged to a variety of
organisations from a number of countries, and who were
for the most part the ﬁnal decision-makers in the
process. However, given that participation was largely
through professional bodies and web-based communi-
ties, we are unable to provide an estimate of our cover-
age. While we took care in designing a survey that
focused on the key determinants of trial site selection,
we may have missed potentially important issues. We
tried to minimise this through preliminary survey review
and reﬁnement with the help of external experts. Also,
although we aimed at obtaining data relative to industry-
sponsored and not-for-proﬁt clinical trials, it is possible
that responses preferentially captured the former. In
addition, some of our questions relating to process and
speed of approval may need further research to deter-
mine the root issues, as problems differ from country to
country, and have to be weighed against the need to
ensure that patient safety remains unprejudiced.
CONCLUSIONS
Our study indicates that fostering European clinical
research and attracting more trials to Europe does not
require additional government spending. Instead, we
believe our ﬁndings support a more harmonised national
adoption of the clinical trial approvals process, greater
visibility of transnational networks of disease experts, and
greater accessibility to research system at national and
pan-European levels. Potential models for improvement
include harmonisation of ethical and institutional
approvals systems, including aligned hospital contracting
and greater visibility of centres of excellence, which may
bring signiﬁcantly more clinical research to Europe.
Europe needs growth, and clinical research can play its
part in directly stimulating economic activity while simul-
taneously boosting European innovation.
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